Sankeetha Nadarajah’s Post

Introducing our latest Advances in Bioanalysis Feature! Explore tailored solutions for cost-effective and timely bioanalysis, learn more about drug development optimization and bioanalysis trends, find out how context of use (COU) influences cell counting in cell therapy manufacturing, and discover how immunoassays drive bioanalysis advancements. #bioanalysis #drugdevelopment

Check out this insightful editorial feature from SelectScience®, where Annika Carlsson, Director of Bioanalysis and Services at Mercodia, sheds light on how Mercodia's cost-effective bioanalytical solutions are shaping drug development success ✨ https://lnkd.in/gAuBr4zm #Bioanalysis #DrugDevelopement #Mercodia

Introducing our latest Advances in Bioanalysis Feature! Explore tailored solutions for cost-effective and timely bioanalysis, learn more about drug development optimization and bioanalysis trends, find out how context of use (COU) influences cell counting in cell therapy manufacturing, and discover how immunoassays drive bioanalysis advancements. #bioanalysis #drugdevelopment

Exciting news! The 2nd Peptide-Based Therapeutics Summit has just launched and will return to Boston on April 1–3, 2025! Peptide therapeutics are advancing faster than ever, with breakthroughs in computational tools, medicinal chemistry, and formulations driving innovation from discovery to clinic. However, challenges like cell permeability, oral bioavailability, and structure prediction remain. Join 22+ expert speakers from pharma and biotech to explore strategies for overcoming these hurdles and advancing cutting-edge peptide therapies. Key topics include: - Peptide design & optimization - Oral bioavailability & delivery innovation - Expanding therapeutic applications Check out the full agenda and speakers here: https://ter.li/e7vcjn #PeptideTherapeutics 

Proof of concept of your ADC, as simple as ABC?   Well, by incorporating molecular imaging early in your drug development process it can be. Questions you would be able to answer:   1. Antibody labeling visualizes on/off target binding of the antibody. 2. Payload distribution gives valuable insights in the toxicity and distribution of the chemical payload. 3. Internalization can be visualized to see if your ADC underwent endocytosis (pH activated probe).   Which of these approaches would add value to your drug development process? Let us know in the comments.   #molecularmonday #adc #antibodydrugconjugate #linker #antibody #drugdevelopment #proofofconcept

Thoughts on this? >> BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #healthcare #biotech #pharmaceutical

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

Thoughts on this? >> BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

📢 We are excited to announce the launch of our NEW in vitro PhysioMimix® Bioavailability assay kit: Human 18! Designed to revolutionize the way you profile human oral drug bioavailability during lead optimization and preclinical development, it is the only in vitro bioavailability assessment tool currently available on the market. Ideal for CRO's, Pharma and biotech ADME/DMPK researchers, the kit leverages the expertise of two microphysiological systems (MPS) providers - Altis Biosystems and CN Bio to recreate a fluidically connected primary human RepliGut®-Planar Jejunum/ PhysioMimix Liver-on-a-chip (Gut/Liver) model. The all-in-one, 18-replicate kit offers you instant access to validated tissue models and protocols that you can leverage to generate human gut and liver ADME estimations, and profile oral bioavailability for your therapeutic candidate in vitro, early in the drug development process to better inform downstream decision making. Visit our website to learn more about the latest addition to the growing portfolio of PhysioMimix assay kits. 👉 https://lnkd.in/eWZr4Y3Q #GutLiver #Bioavailability #AssayKit #OrganOnAChip

The power of collaboration in biotech is undeniable, and partnerships between CROs are driving true advancements in in vitro testing! I'm thrilled to highlight the incredible work from CN Bio as they launch a groundbreaking assay kit for profiling human bioavailability in vitro using primary human small intestine cells from Altis Biosystems. This new assay kit enables the co-culture of human liver and intestinal cells in a fluidically linked system, creating a more accurate, human-relevant model for ADME studies. This synergy of expertise from two innovative CROs is a testament to the progress we can achieve together when we pool our knowledge, technologies, and passion for transforming the life sciences industry. This is just the beginning of how in vitro testing can be modernized to better reflect human physiology and improve drug development outcomes.